










































Mutant induced pluripotent stem cell lines recapitulate aspects of
TDP-43 proteinopathies and reveal cell-specific vulnerability
Citation for published version:
Bilican, B, Serio, A, Barmada, SJ, Nishimura, AL, Sullivan, GJ, Carrasco, M, Phatnani, HP, Puddifoot, CA,
Story, D, Fletcher, J, Park, I-H, Friedman, BA, Daley, GQ, Wyllie, DJA, Hardingham, GE, Wilmut, I,
Finkbeiner, S, Maniatis, T, Shaw, CE & Chandran, S 2012, 'Mutant induced pluripotent stem cell lines
recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability' Proceedings of the
National Academy of Sciences, vol 109, no. 15, pp. 5803-5808. DOI: 10.1073/pnas.1202922109
Digital Object Identifier (DOI):
10.1073/pnas.1202922109
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Proceedings of the National Academy of Sciences
Publisher Rights Statement:
Freely available online through the PNAS open access option.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Mutant induced pluripotent stem cell lines recapitulate
aspects of TDP-43 proteinopathies and reveal
cell-speciﬁc vulnerability
Bilada Bilicana,b, Andrea Serioa,b, Sami J. Barmadac,d, Agnes Lumi Nishimurae, Gareth J. Sullivanb, Monica Carrascof,
Hemali P. Phatnanif, Clare A. Puddifootg, David Storya,b, Judy Fletcherb, In-Hyun Parkh, Brad A. Friedmani,
George Q. Daleyj, David J. A. Wyllieg, Giles E. Hardinghamg, Ian Wilmutb, Steven Finkbeinerc,d, Tom Maniatisf,1,
Christopher E. Shawe,1,2, and Siddharthan Chandrana,b,k,1,2
aEuan MacDonald Centre for Motor Neurone Disease Research, bMedical Research Council Centre for Regenerative Medicine, kCentre for Neuroregeneration,
University of Edinburgh, Edinburgh EH16 4SB, United Kingdom; eInstitute of Psychiatry, Medical Research Council Centre for Neurodegeneration Research,
King’s College London, London SE5 8AF, United Kingdom; gCentre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom;
hYale Stem Cell Center, Department of Genetics, Yale School of Medicine, New Haven, CT 06520; fDepartment of Biochemistry and Molecular Biophysics,
Columbia University, New York, NY 10032; jDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Stem Cell Institute, Harvard Medical
School, Boston, MA 02115; cTaube-Koret Center, Hellman Program, and Rodenberry Stem Cell Program, Gladstone Institute of Neurological Disease, San
Francisco, CA 94158; dDepartments of Neurology and Physiology, University of California, San Francisco, CA 94143; and iDepartment of Molecular and Cellular
Biology, Harvard University, Cambridge, MA 02138
Contributed by Tom Maniatis, February 22, 2012 (sent for review January 10, 2012)
Transactive response DNA-binding (TDP-43) protein is the dominant
disease protein in amyotrophic lateral sclerosis (ALS) and a sub-
group of frontotemporal lobar degeneration (FTLD-TDP). Identiﬁca-
tion of mutations in the gene encoding TDP-43 (TARDBP) in familial
ALS conﬁrms a mechanistic link between misaccumulation of TDP-
43 and neurodegeneration and provides an opportunity to study
TDP-43 proteinopathies in human neurons generated from patient
ﬁbroblasts by using induced pluripotent stem cells (iPSCs). Here, we
report the generation of iPSCs that carry the TDP-43 M337V muta-
tion and their differentiation into neurons and functional motor
neurons. Mutant neurons had elevated levels of soluble and deter-
gent-resistant TDP-43 protein, decreased survival in longitudinal
studies, and increased vulnerability to antagonism of the PI3K path-
way.We conclude that expression of physiological levels of TDP-43 in
human neurons is sufﬁcient to reveal a mutation-speciﬁc cell-auton-
omous phenotype and strongly supports this approach for the study
of disease mechanisms and for drug screening.
disease modeling | reprogramming | motor neuron disease |
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Cytoplasmic accumulation of detergent-resistant transactiveresponse DNA-binding (TDP-43) is a pathological hallmark
of both sporadic and inherited FTLD-TDP (a subgroup of
frontotemporal lobar degeneration) and ALS [except superoxide
dismutase 1 (SOD1) and fused in sarcoma (FUS) cases] and
suggests a common pathological mechanism (1–4). Mutations in
the gene encoding TDP-43 (TARDBP) have been identiﬁed in
familial and sporadic ALS (5–8). Several in vitro and in vivo
models established the toxicity of ALS-associated TDP-43 mu-
tations, although the underlying mechanism is unclear (9, 10).
Most cellular and animal models of ALS and FTLD-TDP
pathogenesis involve overexpression of TDP-43 in nonneuronal
or nonhuman cells and cannot be used to investigate the selective
vulnerability of neurons or key molecular events that are unique
to human cells. By contrast, induced pluripotent stem cells (iPSCs)
(11–14) coupled with deﬁned in vitro differentiation protocols
(15–20) offer a model system to investigate disease mechanisms in
a more physiological context. Here, we report the pathological
effects of endogenous mutant TDP-43 in iPSC-derived human
neurons from an ALS patient carrying the M337V mutation.
Results
Generation of iPSCs from TDP-43 M337V Fibroblasts. iPSC lines were
established by using cells from a 56-y-old man with ALS who had
the TDP-43 M337V mutation (8, 21) and from two healthy
controls. Fibroblasts (Fig. 1A) were transduced with retroviral
vectors encoding the reprogramming factors OCT4, SOX2, KLF4,
and c-MYC as described in ref. 13. Colonies with compact human
ES cell (hESC)-like morphology were expanded, and clonal lines
were established for both genotypes (Fig. 1B). All iPSCs used in
the study exhibited silencing of the four transgenes and activation
of endogenous OCT4, SOX2, and KLF4 (Fig. S1A). All iPSCs
expressed the protein markers of pluripotency—OCT4, SOX2,
and TRA-1-60 (Fig. 1 C and D and Fig. S1B)—and had compa-
rable levels of OCT4, SOX2, c-MYC, KLF4, and NANOG ex-
pression, as determined by quantitative RT-PCR (qRT-PCR) (Fig.
1G and Fig. S1C). Pluripotency was conﬁrmed by teratoma for-
mation (Fig. S1D) and bisulﬁte sequencing of the OCT4 promoter
(13) (Fig. 1F). The genetic mutation was conﬁrmed by direct se-
quencing of exon 6 in TARDBP in all lines (Fig. 1E). All clones
were maintained a normal karyotype for more than 40 passages.
TDP-43 M337V Does Not Prevent Differentiation and Functional
Maturation of Motor Neurons (MNs). To assess the effects of
the TDP-43 M337V mutation on neural differentiation and
function, we generated caudalized neuronal populations con-
taining spinal MNs from iPSCs as described previously (21–23).
Feeder-free iPSCs were differentiated into neuroectoderm by
dual-SMAD signaling inhibition (21) (Fig. 2A and Fig. S2A).
Replating generated >90% NESTIN+ and SOX1+ cells (Fig. 2
B and C). PAX6+ neuroepithelial cells (Fig. S2B) were treated
with retinoic acid and purmorphamine to generate NKX6.1 and
OLIG2+ ventral spinal progenitors (Fig. 2A and Fig. S2C), which
differentiated into MNs expressing HB9, β3-tubulin, SMI-32, and
choline acetyltransferase (ChAT) (Fig. 2 D–F and Fig. S2D) (23–
25). Current–clamp recordings from ChAT+ MNs derived from
M337V and control iPSCs revealed tetrodotoxin-sensitive action
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potentials (Fig. 2G and H). Whole-cell voltage–clamp recordings
revealed functional NMDA, AMPA, and GABA receptors that
typify MNs (Fig. S2 E and F). Mature MN cultures also exhibited
spontaneous excitatory postsynaptic currents (EPSCs) that were
blocked by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (Fig.
2I). Thus, both M337V and control iPSC lines generated pheno-
typically and functionally comparable MNs (26–28).
M337V Increases Soluble and Detergent-Resistant TDP-43 Protein
Levels. A deﬁning biochemical feature of diseased ALS and
FTLD-TDP neural tissue is the accumulation of detergent-re-
sistant ∼43-kDa and C-terminal fragments of TDP-43 (29). We
next examined the biochemical proﬁle of TDP-43 in undif-
ferentiated iPSCs. As determined by qRT-PCR, M337V and
control iPSC lines expressed similar levels of TARDBP, the
pluripotency markers TERT and REX1, and histone deacetylase 6
(HDAC6) mRNA (Fig. 3A), the latter of which is regulated by
TDP-43 (30). Western blotting revealed that two independent
M337V iPSC clones had higher levels of full-length TDP-43
in the soluble fraction and C-terminal TDP-43 fragments in
the detergent-resistant fraction than controls (Fig. 3B). Impor-
tantly, TDP-43 fragmentation was not associated with conven-
tional indices of apoptosis [cleaved poly(ADP-ribose) polymerase
(PARP) (Fig. 3B) and annexin V/propidium iodide proﬁling
(Fig. 3C)] (31–33).
Before establishing the biochemical proﬁle of TDP-43 in MN-
containing neuronal populations, we ﬁrst veriﬁed that MN cul-
tures derived from M337V and control 2 (Cont-2) had compa-
rable expression levels of TARDBP, HB9, ChAT, and HDAC6 as
determined by qRT-PCR analysis (Fig. S3A). Furthermore, MN
cultures derived from both M337V and controls showed similar
percentages of SMI-32+ cells by quantitative immunohistochem-
istry (Fig. S3B), altogether indicating comparable differentiation
potential and composition of MN cultures at the point of assay.
Immunoblot analysis revealed that M337V MN cultures from
two independent clones had up to fourfold higher levels of sol-
uble and detergent-resistant TDP-43 than Cont-2 MN cultures
(Fig. 4 A and B). Difference in TDP-43 levels in MN-containing
populations was also evident with Cont-1 MN cultures (see
control lanes in Figs. S3D and S5B). To determine whether this
observation was independent of neuronal cell type and differ-
entiation protocol, we generated caudalized neuronal pop-
ulations that did not contain MNs and compared the amount of
TDP-43 in cultures derived from mutant or control iPSCs (Fig.
S4 A and B). Again, M337V neurons had higher levels of soluble
(2.6 ± 0.46 vs. 1.0 ± 0.13) and insoluble TDP-43 than controls
(Fig. S4 C and D).
We next investigated the subcellular distribution of TDP-43.
Densitometric analysis revealed that strongly SMI-32+ neurons
had signiﬁcantly higher levels of nuclear TDP-43 than SMI-
32− cells (118.89% ± 2.6% vs. 100% ± 2.9%, P < 0.001) (Fig.
4). However, the predominant nuclear localization of TDP-43
did not differ in M337V and control lines (Fig. S4C). Subtle
granular cytoplasmic staining was also detected in SMI-32+
and ChAT+ M337V neurons (Fig. 4 E and F and Fig. S4 E
and F).
TDP-43 M337V Mutation Confers Selective Cellular Vulnerability to
MNs. We next analyzed the survival of M337V and control MNs
under basal conditions by longitudinal ﬂuorescence microscopy.
To speciﬁcally focus on MNs, we transfected M337V and con-
trol cultures with a plasmid encoding enhanced GFP under the
control of the MN-speciﬁc Hb9 promoter described previously
(HB9::GFP; Fig. 5A) (34). Quantiﬁcation of GFP+ neurons
per well conﬁrmed no difference between M337V and control
MN cultures (Fig. S5A). Automated ﬂuorescence microscopy, a
technique that can image thousands of ﬂuorescently labeled
neurons for extended periods of time, was then used to track
individual neurons and determine their time of death. Neuronal
death was marked by abrupt loss of ﬂuorescence or dissolution
of the cell itself, criteria that have proved equally as sensitive
as traditional markers of cell death (35, 36). Kaplan–Meier
survival analysis was used to plot cumulative hazard curves
depicting the risk of death for MNs derived from M337V and
control iPSCs (Fig. 5B). The relative risk associated with the
M337V mutation was calculated by Cox proportional hazards
Fig. 1. Establishment of iPSCs from patient ﬁbroblasts. (A and B) Primary
dermal ﬁbroblasts from an ALS patient (A) formed tightly packed hESC-
like colonies (B) after lentiviral reprogramming with OCT4, SOX2, KLF4,
and c-MYC. (C and D) Immunohistochemical characterization of feeder-
free patient iPSCs for the pluripotency markers OCT4, Tra-1-60, and SOX2.
(E ) Direct sequencing conﬁrmed the M337V mutation in TDP-43 in patient-
derived iPSCs. (F) Bisulﬁte sequencing analysis of the OCT4 promoter in
M337V iPSCs and hESC line H9s. (G) qRT-PCR comparison of total expres-
sion levels of OCT4, KLF4, c-MYC, and SOX2 in M337V and WT iPSCs and
hESC lines H1, Shef4, and Shef6. Values are mean ± SEM. All results are
from M337V iPSC clone 2 (M337V-2) except G and are representative of
iPSC clone M337V-1.
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analysis, demonstrating a hazard ratio of 2.76, indicative of a
276% increase in the risk of death in M337V compared with
control MNs.
We next determined whether the M337V mutation increased
neuronal vulnerability to antagonism of key signaling pathways
necessary for neuronal survival (37). MN-containing cultures
were treated with U0126, a selective inhibitor of MAPK signal-
ing; LY294002, a selective inhibitor of PI3K; or tunicamycin, an
endoplasmic reticulum stressor. After 48 h of treatment, neu-
ronal death was measured by lactate dehydrogenase (LDH) re-
lease. M337V and control MN cultures did not differ in their
response to MAPK inhibition or tunicamycin (Fig. S5 C and D).
However, M337V mutant lines 1 and 2 were signiﬁcantly more
vulnerable than controls were to LY294002 (Fig. 5C), suggesting
an intrinsic susceptibility to PI3K inhibition in neurons derived
from M337V iPSCs.
Discussion
This paper describes an iPSC model of a TDP-43 proteinopathy
in human MNs derived from a patient carrying a pathogenic
TDP-43 mutation. Detailed cell-lineage and functional studies
showed that the TDP-43 M337V mutation does not affect the
functional maturation of neurons, including MNs. However,
neurons carrying the mutation had increased levels of soluble
and detergent-resistant TDP-43 and reduced survival under
basal conditions, suggesting an inherent vulnerability. Mu-
tant neurons were also more susceptible than control neurons to
inhibition of PI3K, an essential signaling pathway in neurons
(38). Thus, the mutant cells recapitulate key aspects of TDP-43
proteinopathies in vitro, including cell-autonomous neuronal
degeneration and the accumulation of insoluble TDP-43. This
model will facilitate mechanistic studies, the identiﬁcation of
therapeutic targets, and eventually the development of treat-
ments for ALS and FTLD-TDP.
TDP-43 is intrinsically prone to aggregation, and ALS-linked
mutations increase its toxicity, tendency to aggregate, and mis-
localization to the cytoplasm (1, 3, 29, 39, 40). Although TDP-43
M337V and control neurons expressed equivalent levels of
TARDBP mRNA, the mutant cells had signiﬁcantly higher levels
of soluble and detergent-resistant TDP-43. Previously, increased
Fig. 2. TDP-43 M337V and control iPSCs can be differentiated into functional MNs. iPSCs or hESCs were directed toward the neuroectodermal lineage
by dual-SMAD signaling inhibition in feeder-free, adherent culture conditions. (A) M337V iPSCs down-regulate OCT4 and NANOG expression in response to
neuralization and up-regulate the lineage-speciﬁc genes SOX1, HOXB4, NKX6.1, and OLIG2 in a temporal order after sequential application of MN patterning
factors retinoic acid (RA) and purmorphamine (P). (B) Neural differentiation was assessed by quantitative immunohistochemical costaining for Nestin and
Sox1 after replating. (C) M337V and control iPSCs and H9 hESCs showed similar efﬁciency in neural differentiation. (D and E) At 4–6 wk of maturation, iPSC-
derived MN progenitors plated on laminin/ﬁbronectin express HB9 and β3-tubulin (D) and HB9 and SMI-32 (E). (F) M337V and control iPSC-derived neural
stem cells (NSCs) generated MNs with equal efﬁciency, as assessed by quantitative immunohistochemistry for HB9. (G and H) Current–clamp traces showed
tetrodotoxin (TTX)-sensitive action potentials in response to injection of depolarizing current in M337V (G) and WT (H) MNs. (G Inset) ChAT and LcY double-
positive neuron from which recording is performed. (I) Sample traces of spontaneous miniature EPSCs recorded from an M337V culture. All miniature EPSC
events were blocked with CNQX. All data are from M337V-2 and Cont-2 iPSCs. Values are mean ± SEM (n = 3). (Scale bars: 10 μm.)











stability of mutant TDP-43 proteins had only been observed in
isogenic transformed cell lines (41). Our ﬁndings suggest that
differences in TDP-43 protein levels result from a posttrans-
lational mechanism rather than from transcriptional differences.
In addition, the mutant proteins do not appear to interfere with
the proposed autoregulatory feedback mechanism proposed for
the control of TDP-43 mRNA levels (42, 43). The dominant
missense mutations located in the C-terminal domain of TDP-43
might inhibit the turnover of the mutant protein or constrain
protein quality-control pathways.
Despite the higher levels of TDP-43 in M337V neurons de-
tected biochemically, we did not see more nuclear TDP-43 than in
controls, as determined by immunoﬂuorescence densitometry.
However, SMI-32+ neurons had higher levels of nuclear TDP-43
in vitro, indicating that TDP-43 protein levels can differ between
neuronal subtypes. In addition, punctate TDP-43 staining in the
soma and cell processes was a consistent ﬁnding. This staining
pattern is compatible with the involvement of TDP-43 in nucle-
ocytoplasmic shuttling of RNA, the association of TDP-43 with
RNA granules in somatodendrites, and the presence of TDP-43
in the microsome fraction of brainstem samples, suggesting active
transport of TDP-43 along the axons (44–47).
Cellular and transgenic models of TDP-43 expression estab-
lished that elevated levels of WT and mutant TDP-43 can be
toxic and that levels of cytoplasmic, rather than nuclear, TDP-43
correlate with cellular toxicity (9, 10, 48). As shown by longitu-
dinal ﬂuorescence microscopy of live MNs, the risk of death
was signiﬁcantly increased by the M337V mutation, suggesting
an inherent cell-autonomous toxicity of the mutation in MNs.
Neuronal health and function are regulated by multiple signals,
including brain-derived neurotrophic factor (BDNF), glial cell-
derived neurotrophic factor, and other trophic factors that
Fig. 3. M337V iPSCs display biochemical features of TDP-43 misaccu-
mulation. (A) M337V and control iPSCs express similar levels of TDP-43, REX1,
TERT, and HDAC6, as determined by qRT-PCR. (B) Immunoblots of the de-
tergent-soluble and -insoluble fractions from feeder-free iPSC lysates. TDP-
43 fragments of ∼35 kDa are enriched in the detergent-resistant fraction of
the M337V iPSC lysates. Soluble or insoluble TDP-43 levels do not correlate
with cleaved PARP. β-Actin served as a loading control. (C) Representative
annexin V/propidium iodide staining by ﬂow cytometry. The percentages of
cells negative for both annexin V and propidium iodide were similar in
M337V-2 (85.6%) and Cont-2 (75.3%) iPSCs, suggesting comparable levels of
cell death under basal conditions.
Fig. 4. M337V neurons have higher levels of soluble and detergent-re-
sistant TDP-43. (A and B) Western blot analysis of M337V-1, M337V-2, and
Cont-2 MN-containing cultures. Three independent extractions are shown
for each cell line. β3-Tubulin was the loading control for soluble fractions (A),
and Ponceau S reversible membrane staining (51) was the loading control for
detergent-resistant fractions (B). Semiquantitative analyses of band signal
intensity was accomplished by using ImageJ. (A) Levels of soluble TDP-43
normalized to β3-tubulin, Cont-2 set to 1: M337V-1 = 3.67 ± 0.58; M337V-2 =
4.54 ± 0.01; Cont-2 = 1.0 ± 0.24. M337V-1 vs. M337V-2, not signiﬁcant;
M337V-1 vs. Cont-2, P = 0.013; M337V-2 vs. Cont-2, P < 0.001, n = 3 in-
dependent extractions. (B) Levels of detergent-resistant TDP-43 normalized
to Ponceau S, Cont-2 set to 1: M337V-1 = 1.52 ± 0.08; M337V-2= 1.67 ± 0.10;
Cont-2 = 1.0 ± 0.16. M337V-1 vs. M337V-2, not signiﬁcant; M337V-1 vs. Cont-
2, P = 0.04; M337V-2 vs. Cont-2, P < 0.03, n = 3 independent extractions.
Values are mean ± SEM. Data were analyzed by one-way ANOVA and post
hoc Tukey test. (C and D) Immunoﬂuorescence analysis of nuclear TDP-43 in
SMI-32+ and SM-I32− cells. Cont-2 SMI-32+ (118.89% ± 2.6%) vs. SMI-32−
(100% ± 2.9%), P < 0.001, n = 40 cells for each group. (E) M337V iPSC-de-
rived SMI-32+ MNs displayed predominantly nuclear TDP-43 localization with
granular staining present in soma and neurites. (F) Orthogonal views
through one TDP-43 M337V SMI-32+ cell demonstrating localization of TDP-
43 (green), SMI-32 (red), and DAPI (blue). (Scale bars: 10 μm.)
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signal through receptor tyrosine kinases (37). We demonstrated
that M337V neurons were more sensitive to PI3K inhibition
than control neurons were but showed no difference in vul-
nerability to inhibitors of the MAPK pathway or induction of
endoplasmic reticulum stress through tunicamycin. Thus, the
M337V mutation confers a speciﬁc susceptibility to PI3K in-
hibition, highlighting the importance of trophic factor-mediated
signaling in the survival of human MNs. Even though most
neurotrophic factors rely on both MAPK/ERK and PI3K/AKT
pathways for signal transduction, the contribution of these
pathways to cell survival depends on the neuronal subtype and
the combination of trophic factors (38). For instance, BDNF-
induced MN survival requires the PI3K pathway (49), whereas
retinal ganglion cells rely on both the PI3K and MAPK pathways
in BDNF-dependent survival (50). Future studies involving the
in vitro model that we established herein will focus on the con-
tribution of different neurotrophic factors to the survival of
TDP-43 M337V neurons.
In summary, our ﬁndings show that patient-derived TDP-43
M337V neurons recapitulate key biochemical aspects of TDP-43
proteinopathies and provide evidence that the M337V mutation
in TDP-43 is toxic to iPSC-derived MNs, rendering them par-
ticularly susceptible to antagonism of PI3K signaling. Although this
study was limited to a single patient line with subclones and con-
trols, we identiﬁed a disease-speciﬁc phenotype in TDP-43 iPSC
lines. Such lines will be useful for exploring the pathogenic mech-
anisms of other TDP-43 mutations and of different ALS-causing
mutations under basal and stress paradigms. Finally, our ﬁndings
demonstrate the utility of patient-speciﬁc iPSC lines in modeling
the molecular pathogenesis of adult neurodegenerative disorders.
Materials and Methods
Generation of Human iPSCs. Fibroblasts from a normal male (56 y old; CRL-
2465; ATCC), a normal female (40 y old; CRL-2524; ATCC), and from a 56-y-old
male carrying theM337V TDP-43mutationwere reprogrammed as previously
described (13). Details of iPSC characterization are provided in SI Materials
and Methods.
Cell Culture. Human iPSC and hESC lines were maintained long term on CF-1
irradiated mouse embryonic ﬁbroblasts, with KO-DMEM (Invitrogen) sup-
plemented with 20% Knockout Serum Replacement (Invitrogen), 10 ng/mL
basic FGF2 (PeproTech), 1 mM L-glutamine (Invitrogen), 100 mM 2-mer-
captoethanol (Invitrogen), 1% penicillin/streptomycin (Invitrogen), and
1% nonessential amino acids. For the neural conversion, the cells were
transitioned to feeder-free culture conditions in MTESR1 media (Stem
Cell Technologies) and passaged three times before use. Details of neu-
ronal differentiation and characterization are provided in SI Materials
and Methods.
Primers and Antibodies. TaqMan and SYBR Green primer sequences are
provided in Tables S1 and S2, respectively. Primary antibodies used are listed
in Table S3.
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time survival analysis of M337V-1, M337V-2, Cont-1, and Cont-2 MN-containing cultures showing cumulative risk of death of HB9::GFP-transfected neurons.
Pooled data from three independent differentiation experiments are shown (P < 0.001 between mutant and control groups, log-rank test). (C) Cytotoxicity in
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